Mai Onishi

Chuo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).

Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).

Journal: Breast cancer (Tokyo, Japan)
Published: December 04, 2024

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.

Journal: Anticancer research
Published: March 21, 2024

Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.

Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.

Journal: Virchows Archiv : an international journal of pathology
Published: May 19, 2023

Isotropy of Cosmic Rays beyond 10^{20}  eV Favors Their Heavy Mass Composition.

Isotropy of Cosmic Rays beyond 10^{20}  eV Favors Their Heavy Mass Composition.

Journal: Physical review letters
Published: March 24, 2023

TP53 Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer.

TP53 Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer.

Journal: Anticancer research
Published: January 21, 2023

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.

Journal: Breast cancer (Tokyo, Japan)
Published: January 13, 2023

The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.

The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.

Journal: Anticancer research
Published: February 25, 2022

Short- and long-term outcomes of immediate breast reconstruction surgery after neoadjuvant chemotherapy.

Short- and long-term outcomes of immediate breast reconstruction surgery after neoadjuvant chemotherapy.

Journal: Surgery today
Published: December 11, 2020

A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection

A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: July 17, 2020

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).

Journal: Breast cancer (Tokyo, Japan)
Published: June 24, 2020

Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer

Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: July 13, 2019

Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.

Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.

Journal: Surgery today
Published: April 30, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026